**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender 31 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Report Status

**Mobile No.** 9589080439

### **BIOCHEMISTRY**

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 92.9
 mg/dl
 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP ) 114.3 mg/dl Non – Diabetic: - < 140 mg/dl Pre – Diabetic: - 140-199 mg/dl

Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

Т3	1.290	ng/mL	0.970 - 1.690
T4	7.73	ug/dl	5.53 - 11.00
TSH	3.73	μIU/mL	0.40 - 4.05

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Patient Name	Mrs. PAYAL BHARGAVA	Lab No	4028337
UHID	40012049	Collection Date	23/03/2024 9:06AM
Age/Gender IP/OP Location	31 Yrs/Female	Receiving Date	23/03/2024 9:09AM
	O-OPD	Report Date	23/03/2024 2:48PM
Referred By	Dr. EHS CONSULTANT	Report Status	Final
Mobile No.	9589080439		

#### **BIOCHEMISTRY**

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

1.6

8.0

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.54	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.34	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.20	mg/dl	0.00 - 0.30	
SGOT	14.0	U/L	0.0 - 32.0	
SGPT	6.9	U/L	0.0 - 33.0	
TOTAL PROTEIN	7.2	g/dl	6.6 - 8.7	
ALBUMIN	4.4	g/dl	3.5 - 5.2	
GLOBULIN	2.8		1.8 - 3.6	
ALKALINE PHOSPHATASE	70	U/L	35 - 104	

Ratio

U/L

1.5 - 2.5

0.0 - 40.0

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

A/G RATIO

**GGTP** 

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID **Collection Date** 23/03/2024 9:06AM 40012049 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female Report Date O-OPD **IP/OP Location** 23/03/2024 2:48PM Referred By Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9589080439

#### **BIOCHEMISTRY**

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	148		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	48.4		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	93.0		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	11	mg/dl	10 - 50
TRIGLYCERIDES	55		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3	%	

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9589080439

#### **BIOCHEMISTRY**

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	22.30	mg/dl	16.60 - 48.50
BUN	10	mg/dl	6 - 20
CREATININE	0.63	mg/dl	0.50 - 0.90
SODIUM	138	mmol/L	136 - 145
POTASSIUM	3.89	mmol/L	3.50 - 5.50
CHLORIDE	104.6	mmol/L	98 - 107
URIC ACID	4.2	mg/dl	2.4 - 5.7
CALCIUM	9.41	mg/dl	8.60 - 10.00

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID **Collection Date** 23/03/2024 9:06AM 40012049 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female Report Date O-OPD **IP/OP Location** 23/03/2024 2:48PM

Referred By Dr. EHS CONSULTANT Report Status Final

**Mobile No.** 9589080439

#### **BIOCHEMISTRY**

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.
URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.
SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.
POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

HBA1C 5.1 % < 5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

 ${\tt Method: - Turbidimetric\ inhibition\ immunoassay\ (TINIA)}$ 

Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 5 Of 11

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM **Referred By** Final

Dr. EHS CONSULTANT **Report Status** 

Mobile No. 9589080439

### **BLOOD BANK INVESTIGATION**

**Biological Ref. Range Test Name** Result Unit

"AB" Rh Positive **BLOOD GROUPING** 

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

**Patient Name** Lab No Mrs. PAYAL BHARGAVA 4028337 **Collection Date** 23/03/2024 9:06AM UHID 40012049 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date** O-OPD **IP/OP Location** 23/03/2024 2:48PM Dr. EHS CONSULTANT **Referred By Report Status** Final

**Mobile No.** 9589080439

### **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	5.0 L		5.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	
BACTERIA	NIL		NIL	
OHTERS	NIL		NIL	

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Mrs. PAYAL BHARGAVA **Patient Name** Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender 31 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

**Mobile No.** 9589080439

#### Methodology:-

Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

RESULT ENTERED BY : SUNIL EHS

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9589080439

#### **HEMATOLOGY**

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.1	g/dl	12.0 - 15.0
PACKED CELL VOLUME(PCV)	37.6	%	36.0 - 46.0
MCV	90.2	fl	82 - 92
MCH	29.0	pg	27 - 32
MCHC	32.2	g/dl	32 - 36
RBC COUNT	4.17	millions/cu.mm	3.80 - 4.80
TLC (TOTAL WBC COUNT)	4.93	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	63.3	%	40 - 80
LYMPHOCYTE	27.4	%	20 - 40
EOSINOPHILS	3.0	%	1 - 6
BASOPHIL	0.6 L	%	1 - 2
MONOCYTES	5.7	%	2 - 10
PLATELET COUNT	2.78	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 15 mm/1st hr 0 - 15

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

**Patient Name** Lab No Mrs. PAYAL BHARGAVA 4028337 23/03/2024 9:06AM UHID 40012049 **Collection Date** 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date** O-OPD **IP/OP Location** 23/03/2024 2:48PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9589080439

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : SUNIL EHS

Page: 10 Of 11

**Patient Name** Mrs. PAYAL BHARGAVA Lab No 4028337 UHID 40012049 **Collection Date** 23/03/2024 9:06AM 23/03/2024 9:09AM Age/Gender **Receiving Date** 31 Yrs/Female **Report Date IP/OP Location** O-OPD 23/03/2024 2:48PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final 9589080439 Mobile No.

X Ray

Test Name Result Unit Biological Ref. Range

### X-RAY CHEST P. A. VIEW

Both lung fields areclear.

Both CP angles areclear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is withinnormal limits.

Visualized bony thoraxis unremarkable.

Correlate clinically & with other related investigations.

\*\*End Of Report\*\*

RESULT ENTERED BY : SUNIL EHS

Gurer ..

Dr. SURESH KUMAR SAINI

MBBS,MD RADIOLOGIST

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40012049 (8908)	RISNo./Status:	4028337/
Patient Name:	Mrs. PAYAL BHARGAVA	Age/Gender:	31 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	23/03/2024 8:46AM/ OPSCR23- 24/16479	Scan Date :	
Report Date:	23/03/2024 12:16PM	Company Name:	Final

REFERRAL REASON: HEALTH CHECKUP

### 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

### **M MODE DIMENSIONS: -**

III III DE DIIIE	15101151		No	rmal				Normal
IVSD	10.2	6-12mm			LVIDS	25.4	20-40mm	
LVIDD	37.7		32-	57mm		LVPWS	15.8	mm
LVPWD	10.2		6-1	2mm		AO	24.5	19-37mm
IVSS	14.8		J	mm		LA	30.6	19-40mm
LVEF	62-64		>	55%		RA	-	mm
	DOPPLEI	R MEA	SUREN	1ENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY		VELOC	CITY (m/	<b>'s</b> )	GRADIENT		REGURGITATION
				,		(mmHg <u>)</u>		
MITRAL	NORMAL	$\mathbf{E}$	1.06	e'	-	-		NIL
VALVE		A	0.62	E/e'	-			
TRICUSPID	NORMAL		E 0.57		-		NIL	
VALVE			A 0.42					
AORTIC	NORMAL	1.48		-		NIL		
VALVE								
PULMONARY VALVE	NORMAL		0.73		-		NIL	
1	1	1						I

### **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

## **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40012049 (8908)	RISNo./Status:	4028337/
Patient Name:	Mrs. PAYAL BHARGAVA	Age/Gender:	31 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No:	23/03/2024 8:46AM/ OPSCR23- 24/16479	Scan Date :	
Report Date :	23/03/2024 10:29AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

### **ULTRASOUND STUDY OF WHOLE ABDOMEN**

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

**Gall Bladder:** Lumen is clear. Wall thickness is normal. CBD is normal.

**Pancreas:** Normal in size & echotexture.

**Spleen:** Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

Uterus: Normal in size, shape & anteverted in position. Endometrial thickness is normal.

Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.

**Both ovaries:** Bilateral ovaries are normal in size, shape & volume.

Others: Mild free fluid seen in pelvic and POD.

IMPRESSION: USG findings are suggestive of

• No significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

DR. APOORVA JETWANI

**Incharge & Senior Consultant Radiology** 

MBBS, DMRD, DNB Reg. No. 26466, 16307

Page 1 of 1